Last reviewed · How we verify
Herombopag tablets
Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells.
Herombopag is a thrombopoietin (TPO) receptor agonist that stimulates platelet production by binding to and activating the TPO receptor on megakaryocyte progenitor cells. Used for Thrombocytopenia in patients with chronic liver disease, Immune thrombocytopenia (ITP).
At a glance
| Generic name | Herombopag tablets |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Drug class | Thrombopoietin receptor agonist |
| Target | TPO receptor (c-Mpl) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 3 |
Mechanism of action
Herombopag works by mimicking the action of endogenous thrombopoietin, a cytokine that regulates megakaryopoiesis and platelet production. By activating the TPO receptor (c-Mpl), it promotes the proliferation and differentiation of megakaryocytes, leading to increased platelet counts. This mechanism is used to treat thrombocytopenia in patients with chronic liver disease or immune thrombocytopenia.
Approved indications
- Thrombocytopenia in patients with chronic liver disease
- Immune thrombocytopenia (ITP)
Common side effects
- Headache
- Dizziness
- Abdominal pain
- Nausea
- Thromboembolic events
Key clinical trials
- Herombopag Treated T-DM1 Induced Platelet Reduction (PHASE2)
- A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma (PHASE2)
- Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 Study (PHASE2)
- The Phase III Clinical Study of Herombopag for the Treatment of Thrombocytopenia in Chronic Liver Disease Patients Undergoing Elective Invasive Surgery (PHASE3)
- Primary Prevention of Thrombocytopenia Associated With T-DM1 Therapy in HER2 Positive Breast Cancer With Herombopag (NA)
- A Clinical Study on the Efficacy and Safety of Herombopag in the Treatment of Senile Primary ITP (PHASE2)
- A Multicentre Real-world Study of Heptapopal Ethanolamine Tablets in Concurrent/Sequential Radioimmunoinduced Thrombocytopenia
- Study of the Food Effects of Herombopag Olamine Tablets in Healthy Subjects. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |